AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Aug 13, 2026

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

AngioDynamics NASDAQ: ANGO expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and toward higher-growth medical technology platforms, executives said during a Canaccord fireside chat.

MarketBeat • Aug 11, 2026

ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?

AngioDynamics' 33.5% three-month rally rests on Med Tech growth, but valuation, tariffs and negative earnings keep execution risks high.

Zacks Investment Research • Aug 6, 2026

ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus

AngioDynamics' fiscal 2027 outlook hinges on Med Tech growth offsetting flat device sales as tariffs, spending and losses pressure margins.

Zacks Investment Research • Aug 6, 2026

Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?

AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.

Zacks Investment Research • Aug 6, 2026

AngioDynamics to Participate in Upcoming Investor Conferences

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management team is scheduled to participate in the following upcoming investor conferences: 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference Monday, August 10, 2026 Canaccord Genuity's 4.

Business Wire • Jul 28, 2026

AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)

AngioDynamics develops tools for minimally invasive procedures across blood flow, blocked arteries, and prostate cancer treatment. Key offerings include AlphaVac and AngioVac for clot removal, Auryon for arterial plaque, and NanoKnife for prostate cancer. After a prolonged period of stagnation, ANGO shares are finally showing signs of positive momentum.

Seeking Alpha • Jul 16, 2026

AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands

ANGO's Q4 FY26 revenues rise 8% as Med Tech surges, while its adjusted loss beats estimates and FY27 sales guidance tops consensus.

Zacks Investment Research • Jul 15, 2026

AngioDynamics Q4 Earnings Call Highlights

AngioDynamics NASDAQ: ANGO reported higher fiscal fourth-quarter and full-year revenue, driven by continued growth in its med tech portfolio, while management said the company remains focused on balancing investment in clinical programs with profitability and cash generation.

MarketBeat • Jul 14, 2026

AngioDynamics, Inc. (ANGO) Q4 2026 Earnings Call Transcript

AngioDynamics, Inc. (ANGO) Q4 2026 Earnings Call Transcript

Seeking Alpha • Jul 14, 2026